The Indian Council of Medical Research (ICMR) has approved 21 institutions for participating in a randomised controlled study to assess the safety and efficacy of convalescent plasma to limit complications associated with COVID-19, reported The Financial Express.
The sample size of the study is 452, and once 400 patients are enrolled, no more sites will be added.
"We have received an overwhelming response. Expression of interest was received from 111 institutions. As of May 4, the ICMR has approved 21 institutions in the [Phase II] PLACID trial," an official said.
To read more NewsPoints articles, click here.